Only a third of eligible breast cancer patients receive a gene expression test
Research from the Netherlands Comprehensive Cancer Centre indicates that only one-third of eligible breast cancer patients receive gene expression tests, despite the availability of reimbursement. These tests are crucial for determining whether chemotherapy is necessary, yet adoption remains lower than expected.
Why it matters
It highlights a gap in healthcare delivery where policy changes like reimbursement do not automatically translate into optimal patient outcomes.
edited by Gaby Clark , reviewed by Andrew Zinin
The article presents medical research findings objectively, focusing on data and public health implications.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in